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PREPARATION AND CHARACTERIZATION OF TOLTERODINE TARTRATE  
PRONIOSOMES 
 
ABSTRACT 
The present work deals with the preparation of Tolterodine tartrate proniosome formulations by 
ether injection method by using different surfactants i.e. span 60 and tween 40 in different ratios.  
The prepared proniosomal formulation were evaluated for vesicle size analysis, rate of 
spontaneity, encapsulation efficiency, angle of repose, drug content etc. 
In vitro release study conducted for 12 hrs indicated that, increases in liphophilicity of 
surfactants decreases release of Tolterodine tartrate from proniosomal formulations.  
 Stability studies performed at optimized formulation PG4, indicate that, the prepared 
formulations remained more stable at room refrigeration temperature than oven  temperature. 
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INTRODUCTION 
At present scenario vesicular systems have been receiving a lot of interest as a carrier for 
advanced drug delivery
1
. Encapsulation of the drug in vesicular structures is one such system, 
which can be expected to prolong the duration of the drug in systemic circulation
2
.   
Proniosomes are water soluble carrier particles that are coated with surfactants and can be 
hydrated to form niosomal dispersion immediately before use in hot aqueous media. Proniosome 
is a dry free flowing, granular product that could be hydrated immediately before use and would 
avoid many of the problems associated with aqueous noisome dispersions and problem of 
physical stability
3
. Proniosome technology offers novel solution for poorly soluble drugs. 
Proniosomes avoid many of the problems associated with aqueous niosome dispersions, and 
problems of physical stability (aggregation, fusion, leaking) could be minimized. The additional 
convenience of the transportation, distribution, storage, and dosing would make ‘dry niosomes’ a 
promising industrial product
4
.  
Tolterodine is used for the treatment of overactive bladder with symptoms of urge urinary in 
continence, urgency and frequency
5
. Use of Tolterodine tartrate is associated with side effects 
like dry mouth and other side effects like constipation, headache, stomach pain and blurred 
vision, often leading to discontinuation of therapy
6
. 
MATERIALS AND METHODS: 
Tolterodine tartrate was obtained as gift sample from Churchbells Pharma Nigeria Limited. Span 
60, tween 40 and cholesterol were procured from Drugfield Pharmaceuticals Limited, Nigeria.  
Diethyl ether was procured from Interpharma Industries Nigeria Limited. All other reagents used 
were of analytical grades. 
Preparation of Proniosomal Gel: 
Ether injection process 
Proniosomes formulations containing Tolterodine tartrate were prepared by taking cholesterol, 
span 60, tween 40 and lecithin in a 50 ml beaker. The mixture was dissolved in diethyl ether and 
the solution was slowly injected into a beaker containing Tolterodine tartrate in phosphate buffer 
saline (pH 7.4). The temperature maintained during the injection was 40-60
o
C. The differences in 
temperature between phases cause rapid vaporization of ether resulting in spontaneous 
vesiculation
7
. 
 
 Table 1: Composition of Tolterodine tartrate pronisomal gel formulations. 
 
Evaluation of proniosome formulations 
Vesicle size analysis:  
Hydration of Tolterodine tartrate proniosomal gel (100 mg) was done by adding saline solution 
(0.9% solution) in a small glass vial with occasional shaking for 10 min. The dispersion was 
observed under optical microscope at 45 x magnification. The sizes of 200-300 vesicles were 
measured using a calibrated ocular and stage micrometer (Erma, Tokyo) fitted in the optical 
microscope
8
. 
Rate of spontaneity: 
Approximately 10 or 20 mg of Tolterodine tartrate proniosomal gel was transferred to the bottom 
of a clean stoppered glass bottle and spread uniformly around the wall of the glass bottle with the 
help of a glass rod. At room temperature, 2 ml of phosphate saline (0.154 M NaCl) was added 
carefully along the walls of the glass bottle and left in a test-tube stand After 20 minutes, a drop 
of this saline solution was withdrawn and placed on Neubauers Chamber (Marienfeld) to count 
the number of vesicles. The number of niosomes eluted from proniosomes was counted
9
. 
Encapsulation efficiency:  
To evaluate the loading capacity of proniosomal systems for Tolterodine tartrate gel (100 mg) 
was dispersed in distilled water and warmed a little for the formation of niosomes. Then the 
dispersion was centrifuged at 18000 rpm for 40 min the clear fraction was used for the 
determination of free drug at 224 nm spectrophotometrically. The percentage encapsulation 
efficiency was calculated from following equation
10
.  
 
                           
                                  
          
      
pH and Viscosity 
Accurately weighed gel was taken and then diluted with the pH 7.4 phosphate buffer and 
checked the pH by using pH meter and Brook field viscometer is used to determine the 
viscosity of the gel
11
. 
Zeta potential analysis 
Zeta potential analysis was determining for the colloidal properties for a prepared 
formulations of Tolterodine tartrate. The proniosomes derived from noisome dispersion will be 
determined using zeta potential analyser based on the Electrophoretic light scattering and laser 
Doppler Velocimetery method. The temperature was set at 25°C and measures the charge on 
vesicles and means zeta potential values12. 
In vitro release study: 
In vitro release studies on proniosomal gel of Tolterodine tartrate were performed using locally 
manufactured Franz-diffusion cell. The capacity of receptor compartment was 15 ml. The area of 
donor compartment exposed to receptor compartment was 1.41cm
2
. The dialysis cellophane 
S.N. 
 
Code Drug (mg) Span 60 
(mg) 
Tween 40 
(mg) 
Diethyl 
ether 
(ml) 
Lecithin 
(mg) 
Cholesterol 
(mg) 
1 PG1 100 1500 - 10 900 200 
2 PG2 100 - 1500 10 1800 400 
3 PG3 100 - 1500 10 900 200 
4 PG4 100 1500 - 10 1800 400 
 membrane (MMCO 14KDC) was mounted between the donor and receptor compartment. A 
weighed amount of proniosomal gel was placed on one side of the dialysis membrane. The 
receptor medium was phosphate saline buffer pH 7.4. The receptor compartment was surrounded 
by a water jacket to maintain the temperature at 37±1
o
C. Samples were withdrawn and were 
replaced by equal volumes of fresh receptor fluid on each occasion. Samples withdrawn were 
analyzed spectrophotometrically at 281 nm
13
. 
Stability Studies: 
The ability of vesicles to retain the drug  was assessed by keeping the proniosomal gel at three 
different temperature conditions, i.e., refrigeration temperature (4-8
0
C), room temperature 
(25±2
0
C) and oven (45±2
0
C) for 12 weeks.Throughout the study, proniosomal formulations of 
Tolterodine tartrate were stored in aluminium foil-sealed glass vials. The samples were 
withdrawn at different time intervals over a period of one month and drug leakage from the 
formulations was analyzed for drug content spectrophotometrically
14
. 
RESULTS AND DISCUSSION: 
Results of vesicle size of Tolterodine tartrate proniosome formulations are presented in (Table2), 
which indicated that vesicle formed with Span 60 is smaller in size than vesicle formed with 
tween 40. The reason for it may be grater hydrophobicity of spans as compared to tweens
15
. As 
hydrophobicity increases, surface energy of surfactants decreases, resulting in smaller vesicle 
size.  Size of vesicle was reduced when dispersion was agitated. The reason for this is the energy 
applied in agitation which results in breakage of larger vesicles to smaller vesicles
16
. The size 
range was found to be 15.28±0.33 to 16.43±0.22 µm. Rate of spontaneity lies in between 
12.20±0.43 to 14.44±0.76. 
Table 2: Characterization of the proniosomal formulations of Tolterodine tartrate. 
Batch 
Code 
Mean 
particle 
size 
µm  
Rate of 
spontaneity 
mm
3
x1000 
Encapsulation 
efficiency (%) 
Angle of 
repose 
% Drug 
content 
 
pH Viscosity 
(cp) 
PG1 15.28±0.33 13.16±0.33 77.2±0.45 34.32
 o
 ±0.43 95±0.32 7.12 7244 
PG2 8.34±0.45 12.20±0.43 79.4±0.39 36.12
 o
 ±0.78 88±0.12 7.34 8247 
PG3 7.27±0.67 14.44±0.76 81.2±0.48 38.21
 o
 ±0.27 90±0.77 7.42 9314 
PG4 16.43±0.22 13.66±0.57 
 
88.3±0.55 36.35
 o
 ±0.06 99±0.47 7.11 7642 
 (Mean± S.D., n=3)   
Encapsulation efficiency was found to be higher in case of proniosome prepared with Span60 
than proniosome prepared with Tween 40. This may be due to more hydrophobic nature of span 
40, as compared to tween 60, which act as solid at room temperature and showed higher phase 
transition temperature (Tc), low HLB value and long alkyl chain length
17
. 
Drug content is important parameter to maintain the minimum effective concentration and it is 
also used to estimate the drug release profile. The percent drug content was higher for PG4 that 
is 99±0.47 % and lower for PG2 (88±0.12%). 
In vitro release studies (figure 1) are often performed to predict how a delivery system might 
work in an ideal situation as well as give some indications of its in vivo performance since drug 
release dictates the amount of drug available for absorption.  
The amount of drug released from different proniosomal  formulations was found in the order of 
PG4 > PG3 > PG2> PG1. In vitro release study performed on different proniosome formulations 
shows maximum release for formulations of batch PG4 (87.45 %), and minimum for 
formulations of batch PG4 (50%), during the study of 12 hrs. It was found that in-vitro release 
 from proniosomal formulations prepared with Tween 40 is slower as compared to proniosomal 
gel formulation prepared with span 60. This was expected due to the larger size of the vesicles
18
. 
 
Figure 1: Comparative in-vitro release study of different proniosome formulations of 
Tolterodine tartrate 
Stability studies performed on optimized formulations PG4 shows 96.74% drug content at 
refrigeration condition, 94.74% drug content at oven condition and 99.59% drug content at room 
temperature during the studies performed for 12 weeks on the formulations (figure 2). Hence it is 
concluded from the obtained data that the optimum storage condition for proniosomes was found 
to be room temperature. 
 
Figure 2: Stability study of optimized gel formulation (PG4) at different temperature 
conditions. 
CONCLUSION 
The results of investigation demonstrated that proniosomes offers an alternative colloidal carrier 
approach. The results obtained from the present study clearly revealed that Tolterodine tartrate 
proniosome formulations prepared by using ether injection method are capable of releasing drug 
for the extended period of time. Results of the present work have shown that surfactant type 
affect the encapsulation efficiency and drug release rate from proniosomes. Based on different 
parameters formulation of batch PG4 was considered as an optimum formulation.   
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